Ampio's Vyrix unit out-licenses certain rights for Zertane to Paladin

10 April 2014

USA-based biotech firm Ampio Pharmaceuticals (NYSE MKT) says its wholly-owned subsidiary Vyrix Pharmaceuticals has signed an agreement with Canada’s Paladin Labs, a subsidiary of Endo Health Solutions (Nasdaq: ENDP), to provide exclusive rights to market, sell and distribute Zertane (tramadol) in Canada, South Africa, Sub-Saharan Africa and Latin America.

The agreement provides for an undisclosed upfront payment, approval and revenue-based milestone payments and an ongoing double-digit royalty stream to Vyrix. Paladin and Vyrix will collaborate to apply for Health Canada approval for Zertane to enable near-term registration in Canada with registrations in other countries in the Territory to follow.

Last year, Ampio announced that it was spinning off its sexual dysfunction business into a standalone company, Vyrix Pharmaceuticals, after it failed to find a development partner for Zertane (The Pharma Letter December 16, 2013).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK